

## Vancomycin injection - New warning

- On September 28, 2017, the <u>FDA approved</u> an update to the *Warnings* section of the <u>vancomycin</u> injection drug label regarding hemorrhagic occlusive retinal vasculitis (HORV).
- Vancomycin is indicated for the following:
  - Treatment of serious or severe infections caused by susceptible strains of methicillinresistant (beta-lactam-resistant) staphylococci.
  - For penicillin-allergic patients, for patients who cannot receive or who have failed to respond
    to other drugs, including the penicillins or cephalosporins, and for infections caused by
    vancomycin-susceptible organisms that are resistant to other antimicrobial drugs.
  - For initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly.
- HORV, including permanent loss of vision, occurred in patients receiving intracameral or intravitreal administration of vancomycin during or after cataract surgery. The safety and efficacy of vancomycin administered by the intracameral or the intravitreal route have not been established by adequate and well controlled trials. Vancomycin is not indicated for prophylaxis of endophthalmitis.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.